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Abstract
Acute lung injury (ALI) is a severe hypoxemic respiratory
insufficiency associated with lung leak, diffuse alveolar
damage, inflammation, and loss of lung function. Decreased
dimethylaminohydrolase (DDAH) activity and increases in
asymmetric dimethylarginine (ADMA), together with exaggerated
oxidative/nitrative stress, contributes to the development of
ALI in mice exposed to LPS. Whether restoring DDAH
function and suppressing ADMA levels can effectively ameliorate
vascular hyperpermeability and lung injury in ALI is unknown,
and was the focus of this study. In human lung microvascular
endothelial cells, DDAH II overexpression prevented the LPS-
dependent increase in ADMA, superoxide, peroxynitrite, and
protein nitration. DDAH II also attenuated the endothelial
barrier disruption associated with LPS exposure. Similarly,
in vivo, we demonstrated that the targeted overexpression of
DDAH II in the pulmonary vasculature significantly inhibited the
accumulation of ADMA and the subsequent increase in oxidative/
nitrative stress in the lungs of mice exposed to LPS. In addition,
augmenting pulmonary DDAH II activity before LPS exposure
reduced lung vascular leak and lung injury and restored lung
function when DDAH activity was increased after injury.
Together, these data suggest that enhancing DDAH II
activity may prove a useful adjuvant therapy to treat
patients with ALI.
Keywords: dimethylarginine dimethylaminohydrolase II;
asymmetric dimethylarginine; nitrative stress; acute lung injury;
gene delivery
Clinical Relevance
Nitrosative stress is now recognized as an important player in
acute lung injury (ALI). However, the mechanisms underlying
this process are unclear. Our data show that increases in
asymmetric dimethylarginine (ADMA) lead to nitrosative
stress, and scavenging ADMA, through dimethylarginine
dimethylaminohydrolase (DDAH) overexpression, prevents
ALI in vivo. Thus, targeting the ADMA/DDAH pathway may
have clinical utility for the treatment of ALI/acute respiratory
distress syndrome.
Acute lung injury (ALI) is an inflammatory
disorder associated with high morbidity and
mortality. ALI can occur in response to
a number of direct insults, such as viral or
bacterial infections of the lung, hyperoxia,
and acid aspiration, or indirect insults,
such as sepsis, multiple transfusions, and
pancreatitis. LPS from the outer cell wall of
gram-negative bacteria can induce
a systemic inflammatory response, which is
the most common indirect pulmonary insult
leading to ALI (1). LPS provokes damage
to the alveolar–capillary membrane and the
adhesion, activation, and sequestration of
polymorphonuclear neutrophils, which
result in the deterioration of gas exchange
and increased pulmonary capillary
permeability (2). A number of ventilator
and pharmacologic therapies, such as
corticosteroids, prostacyclins, exogenous
surfactants, ketoconazole, and nitric oxide
(NO) (3), have been tested in large,
randomized trials, but, to date, only
mechanical ventilation with low tidal
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volumes has been shown to improve
survival (4). Therefore, there is a further
need to study the pathophysiology of ALI
and identify new therapeutic targets to
improve patient outcome.
Recently completed studies from our
laboratory have indicated that asymmetric
dimethylarginine (ADMA) levels are
increased during ALI (5). High plasma
levels of ADMA have previously been
associated with cardiovascular disorders,
including atherosclerosis, hypertension,
homocysteinemia, diabetes mellitus, insulin
resistance, and hypercholesterolemia (6–10).
Increased ADMA levels impair endothelial
function in these cardiovascular diseases
(6–10), but the role of ADMA in the
endothelial barrier disruption associated
with ALI is unknown. ADMA inhibits NO
production by competing with L-arginine
for binding to NO synthase (NOS) (11). In
addition, ADMA can “uncouple” NOS by
shifting the balance of NO production to
superoxide generation (12). We have shown,
both in vitro and in vivo, that increased
levels of ADMA lead to an increase in
NOS uncoupling and enhanced cellular
generation of peroxynitrite (5, 13). Several
studies support the view that the ratio
between L-arginine and ADMA is a key
component in the regulation of endothelial
NOS (eNOS) activity, and elevated ADMA
levels have been demonstrated to antagonize
NOS signaling in humans (6–10).
ADMA is metabolized via hydrolytic
degradation to citrulline and dimethylamine
by the enzymes, dimethylarginine
dimethylaminohydrolase (DDAH) I and II (10).
Our recently completed study indicated that
ADMA levels are increased in the lungs of
mice exposed to LPS secondary to a decrease in
DDAH activity (5). In the present study, we
found that increasing DDAH II activity in vitro
and in vivo attenuated the LPS-induced
increase in ADMA, reduced both oxidative and
nitrative stress, and prevented the disruption
of endothelial barrier function, suggesting that
the DDAH–ADMA axis may be a potential
therapeutic target for the management of
patients with ALI. Furthermore, we found that
increasing DDAH activity could both preserve
and restore lung function.
Materials and Methods
Animal Treatments
Adult male C57BL/6NHsd mice (7–8 wk;
Harlan, Indianapolis, IN) were used in all
experiments. All animal care and
experimental procedures were approved by the
Committee on Animal Use in Research and
Education of the Georgia Regents University.
The pre- and postinjury models induced by
LPS exposure are described in the MATERIALS
AND METHODS in the online supplement.
In Vivo Overexpression of DDAH II
In vivo polyethyleneimine derivative
transfection reagent was used to deliver
pAd/CMV/V5-DEST-DDAH II cDNA or
pDST-luciferase to the mouse lung
endothelium via a tail vein injection, as
described in the MATERIALS AND METHODS in
the online supplement.
Luciferase Activity
The luciferase activity in total protein extracts
prepared from brain, liver, lung, heart, and
kidney was determined 1–7 days after
pDST-luciferase injection using the luciferase
assay system (Promega, Madison, WI).
Generation of DDAH II Adenoviral
Expression Vector
An adenovirus expressing the human
DDAH II coding sequence was generated as
described in the MATERIALS AND METHODS in
the online supplement.
Cell Culture
Primary cultures of human lung
microvascular endothelial cells (HLMVECs)
were isolated, as described previously (14).
Western Blot Analysis
Immunoblot analysis was as previously
described (15, 16). The blots were probed with
custom-made antibodies against DDAH I
(1:500 dilution) and DDAH II (1:500 dilution),
as described previously (17). Protein loading
was normalized by reprobing the membranes
with an antibody specific to b-actin.
Measurement of Peroxynitrite and
Protein Nitration Levels
Peroxynitrite and protein nitration level
measurement was performed as described in
the MATERIALS AND METHODS in the online
supplement and previously described (15).
In Vitro Permeability Assays
In vitro permeability was estimated by
measuring transendothelial resistance
(TER), a transwell permeability assay, and
cellular gap analysis, as described in the
MATERIALS AND METHODS in the online
supplement.
Cell Imaging
Cell imaging was performed as described in
the MATERIALS AND METHODS in the online
supplement.
DDAH Activity Assay
Total DDAH activity was determined
using a radioactive assay to measure the
conversion of N-a-Methyl-(L)-arginine
[4,5-3H] to [3H]-L-citrulline, as described
in the MATERIALS AND METHODS in the
online supplement.
Measurement of ADMA Levels
ADMA levels were analyzed by HPLC, as we
have previously described (5).
Determination of Superoxide Levels
NOS-derived superoxide levels were
estimated by electronic paramagnetic




LLC, Farmingdale, NY) in the presence
of ethylisothiourea (100 mM, 30 min;




Isolation of bronchoalveolar lavage fluid
(BALF) was performed as described in the




A total of 32 different cytokines/chemokines
were assessed in the BALF, as described
in the MATERIALS AND METHODS in the online
supplement.
Myeloperoxidase Staining and
Histological Analysis of the
Mouse Lung
Myeloperoxidase (MPO) staining and
histological analysis of the mouse lung
were performed as described in the
MATERIALS AND METHODS in the online
supplement.
MPO Activity
MPO activity in snap-frozen mouse lung
tissue was determined using an MPO assay
kit (BioVision, Inc., Milpitas, CA),
according to the manufacturer’s
instructions.
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Determination of DDAH II Localization
Determination of DDAH II localization was
performed as described in the MATERIALS
AND METHODS in the online supplement.
Vascular Leak Assessment In Vivo
Vascular leak assessment in vivo was
performed as described in the MATERIALS
AND METHODS in the online supplement and
as previously described (19).
Assessment of
Respiratory Mechanics
Lung function tests were performed as
described in the MATERIALS AND METHODS
in the online supplement.
Statistical Analysis
Statistical analysis was performed as
described in the MATERIALS AND METHODS
in the online supplement.
Results
We have previously reported that LPS
increases superoxide and peroxynitrite
levels, and that the scavenging of these free
radicals can reduce lung leak in mice treated
with LPS (5). To determine if LPS exerts
a similar effect in culture, we exposed
HLMVECs to LPS in the presence or
absence of the peroxynitrite scavenger,
Mn(III)tetrakis(1-methyl-4-pyridyl)
porphyrin, and measured changes in
endothelial barrier function. Our results
show that Mn(III)tetrakis(1-methyl-4-
pyridyl)porphyrin attenuated the LPS-
induced decrease in TER (Figure 1A), the
LPS-mediated increase in transendothelial
flux of FITC-dextran (Figure 1B), and the
formation inter- and intra-cellular gaps
(Figures 1C and 1D), indicating that
oxidative/nitrative stress is involved in LPS-
mediated barrier dysfunction in
HLMVECs.
In a recent study, we correlated
increased peroxynitrite generation with
increased ADMA-mediatedNOS uncoupling
(5). To begin to determine if DDAH II
overexpression could prevent these changes,
we initially developed an adenoviral
expression construct for DDAH II (Adv
DDAH II). The transduction of HLMVECs
with Adv DDAH II significantly increased
both DDAH II protein levels (Figure 2A) and
DDAH activity (Figure 2B). In HLMVECs
exposed to LPS, there was a significant
increase in ADMA levels (Figure 2C), and
this correlated with an increase in NOS-
derived superoxide (Figure 2D), peroxynitrite
generation (Figure 2E), and nitrated proteins
(Figure 2F). However, when HLMVECs
were transduced with Adv DDAH II, the
LPS-mediated increase in ADMA levels
(Figure 2C), NOS-derived superoxide
(Figure 2D), peroxynitrite formation
(Figure 2E), and protein nitration (Figure 2F)
were all significantly decreased. In addition,
DDAH II overexpression attenuated the LPS-
mediated disruption of the endothelial barrier,
as demonstrated by a preservation of TER
(Figure 3A), an attenuation of the
transendothelial flux of FITC-dextran
(Figure 3B), and a decrease in the formation
of inter- and intra-cellular gaps (Figures 3C
and 3D). In contrast, the small interfering
RNA–mediated knockdown of DDAH II
in HLMVECs, which resulted in a 50%
Figure 1. Peroxynitrite scavenging attenuates the LPS-mediated decrease in barrier function in human lung microvascular endothelial cells (HLMVECs).
HLMVECs were challenged with LPS (1 EU/ml, 0–12 h) in the presence or absence of the peroxynitrite scavenger, Mn(III)tetrakis(1-methyl-4-pyridyl)
porphyrin (MnTmPyP; 25 mM, 30 min before LPS, with LPS, and 1 h after LPS treatment). LPS decreased the normalized transendothelial resistance (TER),
and this was significantly attenuated by MnTMPyP (A). Similarly, the LPS-mediated (1 EU/ml, 4 h) extravasation of FITC-dextran was significantly reduced in cells
pretreated with MnTMPyP (25 mM) (B). In addition, immunofluorescent analysis of vascular endothelial–cadherin (C) indicates that the LPS-mediated increase in
gap formation was also attenuated by MnTMPyP (D). Values are mean 6 SEM (n = 3–7). *P , 0.05 versus control, †P , 0.05 versus LPS alone.
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reduction in DDAH II protein (Figure 3E),
significantly decreased basal TER
(Figure 3F).
To determine if the loss of DDAH
activity plays an important role in the
development of ALI in vivo, we used the
polyethyleneimine derivative transfection
reagent to deliver a DDAH II expression
plasmid into the mouse lung. Initial
Figure 2. Dimethylarginine dimethylaminohydrolase (DDAH) II attenuates LPS-induced increase in asymmetric dimethylarginine (ADMA), superoxide, and
peroxynitrite levels in HLMVECs. HLMVECs were transduced with adenoviruses expressing either GFP (Adv GFP; as a control) or DDAH II (Adv DDAH II)
for 48 hours. Immunoblot analysis demonstrated a twofold increase in DDAH II protein without alterations in DDAH I protein (A). DDAH activity,
estimated by the conversion of N-a-Methyl-(L)-arginine [4,5-3H] to [3H]-L-citrulline, was also significantly increased in the DDAH II–overexpressing cells (B).
HLMVECs were also challenged with LPS (1 EU/ml, 4 h) after transduction with Adv GFP (as a control) or Adv DDAH II. LPS exposure increased ADMA
levels in the Adv GFP–transduced cells, but not in the cells transduced with Adv DDAH II (C). LPS induced a significant increase in nitric oxide (NO)
synthase (NOS)–derived superoxide radical generation in the control cells, and this was attenuated in cells overexpressing DDAH II (D). Nitrative stress
was estimated using the peroxynitrite-dependent oxidation of dihydrorhodamine (DHR) 123 to rhodamine 123 and 3-nitrotyrosine (3-NT) levels using
dot blot analysis. The LPS-mediated increase in peroxynitrite (E) and 3-NT (F) in the control cells was prevented by DDAH II overexpression. Values are
mean 6 SEM (n = 3–5). *P , 0.05 versus control, †P , 0.05 versus LPS.
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experiments verified that the tail vein
injection of a luciferase reporter plasmid
(pDST-luciferase) resulted in the
preferential expression of the plasmid in
the lung (Figure 4A), and that the
expression peaked in the lung 3 days after
injection (Figure 4B). Furthermore, when
a V5-tagged DDAH II expression plasmid
was used, immunohistochemical analysis
identified preferential expression in the
pulmonary endothelium, as evidenced by
the colocalization of DDAH II and the
endothelial marker, Von Willebrand
factor, on a hematoxylin background
(Figure 4 C) and immunofluorescent
Figure 3. DDAH II overexpression prevents the LPS-induced barrier disruption in HLMVECs. HLMVECs were transduced with Adv GFP (as a control) or
Adv DDAH II. After 48 hours, the cells were challenged with LPS (1 EU/ml, 0–12 h). TER was decreased in response to LPS in the control cells,
whereas, in the cells overexpressing DDAH II, the decrease in TER was significantly attenuated (A). Similarly, the LPS-mediated (1 EU/ml, 4 h)
extravasation of FITC-dextran was significantly attenuated in cells overexpressing DDAH II (B). HLMVECs were also transfected with either pcDNA3
(control) or pcDNA3-DDAH II-His6 plasmid (DDAH II), and exposed to LPS (1 EU/ml, 4 h). Immunofluorescent analysis of vascular endothelial–cadherin (C)
indicated that the LPS-mediated increase in gap formation was significantly attenuated in His6-tagged DDAH II–expressing cells (D). When HLMVECs
were transfected with either a scrambled small interfering RNA (siRNA) or DDAH II siRNA for 60 hours to reduce DDAH II protein levels (E), basal TER was
significantly attenuated (F). Values are mean 6 SEM (n = 4–5). *P , 0.05 versus control or scrambled (Scr) siRNA, †P , 0.05 versus LPS.
ORIGINAL RESEARCH
618 American Journal of Respiratory Cell and Molecular Biology Volume 50 Number 3 | March 2014
staining (Figure 4D). Using this technique,
we were able to identify a significant
increase in DDAH II protein levels
(Figure 4E) and catalytic activity
(Figure 4F) in mouse lung.
In agreement with our in vitro results,
we found that the gene delivery of the
V5-tagged DDAH II expression plasmid,
before the LPS-induced insult, significantly
attenuated the increases in ADMA
(Figure 5A), NOS-derived superoxide
(Figure 5B), peroxynitrite (Figure 5C), and
protein nitration (Figure 5D). In addition,
analysis of the BALF indicated that
DDAH II significantly prevented LPS-
mediated cellular infiltration (Figure 6A).
Using MPO activity (Figure 6B), we found
that DDAH II overexpression also reduced
neutrophil infiltration in the LPS-treated
mouse lungs. The BALF was also analyzed
for the presence of 32 cytokines/
chemokines. Our results demonstrate that
LPS significantly increased the levels of 28
cytokines and chemokines (see Table E1 in
the online supplement), including the
neutrophil chemoattractant, keratinocyte-
derived chemokine (KC; Figure 6C) and
monocyte chemoattractant protein (MCP)
-1 (Figure 6D). The overexpression of
DDAH II attenuated the levels of 13
cytokines induced by LPS (Table E1),
including KC (Figure 6C). However,
DDAH II did not prevent the increase in
MCP-1 (Figure 6D). Lung sections stained
with MPO and hematoxylin and eosin
indicated that DDAH II protected the lungs
against LPS-induced alveolar damage and
histopathological changes, such as the
permeation of leukocytes and red blood
cells in the alveolar and interstitial space,
the formation of hyaline membranes, septal
thickening, and debris accumulation in
the alveoli (Figure 6E). We also assessed
the severity of the lung injury using
a semiquantitative histopathological scoring
system (20), which determines the
thickness of alveolar septae, alveolar
hemorrhage, intra-alveolar fibrin
accumulation, and intra-alveolar
infiltration. DDAH II overexpression
attenuated the lung injury score in the
LPS-treated mice (Figure 6F). Finally, we
found that DDAH II overexpression
significantly attenuated the LPS-induced
vascular leak, as indicated by a reduction
in the extravasation of Evan’s blue dye
(Figure 6G).
Finally, to determine the therapeutic
potential of DDAH II, we developed
Figure 4. The overexpression of DDAH II in the mouse lung. The relative amount of luciferase activity
was detected in homogenates of brain, liver, lung, heart, and kidney after tail vein injection of pDST-
luciferase (40 mg) complexed with polyethyleneimine derivative transfection reagent (Jet-PEI).
Luciferase activity was found to be predominantly localized to the lung (A). Maximum luciferase
activity in the lung was detected 3 days after injection (B). Mice were injected with either DST-
luciferase (DST) or pAD/CMV/V5-DEST-DDAH II (DDAH II-V5) plasmid via tail vein injection, and
DDAH II localization was determined. The image in (C) shows hematoxylin staining with V5-tagged
DDAH II (V5; red) and vascular endothelial cells labeled with anti-Von Willebrand factor (vWF; brown).
The arrows indicate vWF (brown) staining in the control mice, whereas the reddish-brown staining
in the V5-tagged DDAH II tissues is a result of a merger of vWF (brown) and V5 (red). (D) Bright-
field images (left) of pulmonary vessels and fluorescent images (right) of V5-tagged DDAH II (V5; red).
The results from four separate injections show a predominant expression of DDAH II localized to the
endothelial layer (C–D). Furthermore, immunoblot analysis demonstrated a significant increase in
DDAH II protein levels (E), whereas the increased conversion of N-a-Methyl-(L)-arginine [4,5-3H] to
[3H]-L-citrulline demonstrated an increase in DDAH activity, in the lungs receiving DDAH II-V5 plasmid
(F). Values are mean 6 SEM (n = 4–6 per group). *P , 0.05 versus 0 days (B) and DST (E and F).
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a postinjury model by exposing mice to
intratracheal LPS (1.25 mg/kg body weight).
This protocol induced significant lung
injury 4 days after the insult, as determined
by an increase in cell number in the BALF
(Figure 7A). We then delivered the V5-
tagged DDAH II expression plasmid via tail
vein injection on Day 4, and found
a significant increase in DDAH II protein
levels (Figure 7B) and activity (Figure 7C)
in the lungs of mice 3 days after gene
delivery (Day 7 after LPS). Analysis of the
BALF indicated that DDAH II significantly
reduced cellular infiltration on Day 7
after LPS, suggesting that DDAH II
overexpression was accelerating the
resolution phase (Figure 7A). Similarly,
MPO activity was significantly reduced
when DDAH II was delivered on Day 4
after LPS (Figure 7D). The staining of lung
sections with MPO and hematoxylin and
eosin suggested that DDAH II
overexpression after LPS was able to
accelerate lung recovery, as both the
alveolar damage and histopathological
changes were significantly reduced
(Figure 7E). This reduced the lung injury
score on Day 7 after LPS (Figure 7F).
Finally, we found that DDAH II
overexpression significantly improved
lung function, as measured by increased
compliance (Figure 7G), decreased
resistance (Figure 7H), and higher oxygen
saturation (Figure 7I).
Discussion
The findings we present here underline the
important role of diminished DDAH
activity in LPS-induced lung injury. Our
data suggest that attenuating ADMA levels
or increasing DDAH activity prevents
NOS uncoupling, reduces superoxide
generation, and inhibits oxidative/nitrative
damage. Although the NOS isoform
responsible for the increase in superoxide in
our study has not yet been determined,
ADMA is known to induce the uncoupling
of all the NOS isoforms (15, 24), and is
an effective inhibitor of NO production
from eNOS (8), but only a weak inhibitor of
NO production by inducible NOS (iNOS)
(25). As LPS induces iNOS protein levels in
the mouse lung (5), it is possible that the
increased NOS-derived superoxide and
peroxynitrite formation that we observed
could be generated from both iNOS and
eNOS. In addition, our data indicate that
DDAH II overexpression limits the
inflammatory response and promotes
vascular barrier integrity. Furthermore, the
results obtained using a postinjury model
of ALI that we developed suggest that
DDAH II may also facilitate the recovery
from ALI. This was evident from our data
showing that, in comparison to Day 4 after
LPS, the BALF cellularity on Day 7 after
LPS was significantly lower in DDAH
II–overexpressing mice.
Our data also show that, although
DDAH activity is reduced in the mouse lung
exposed to LPS, DDAH protein levels are
unchanged, suggesting that a post-
translational mechanism is involved. The
DDAH II isoform is thought to be oxidant
sensitive (21) and the predominant
endothelial isoform (12, 36). In an earlier
study, oxidative stress induced by oxidized
low-density lipoprotein or TNF-a
decreased DDAH activity, but not its
protein expression in endothelial cells (22).
Lin and colleagues (38) have shown that
elevated glucose raises endothelial ADMA
levels by inhibiting DDAH activity via
a mechanism involving oxidative stress.
Similarly, in our previous report, we
found that LPS decreased DDAH activity
within 2 hours in mouse lung (5),
suggesting that the attenuation of DDAH
activity is an early post-translational event
in the continuum of lung injury. The
post-translational events responsible for the
attenuation of DDAH activity seem to be
dependent on the nature of the oxidative
stress. For example, it has been reported
that DDAH activity is reversibly inhibited
when recombinant DDAH II or the
cytosolic extracts from rat kidneys are
incubated with NO donors (23). In
cultured endothelial cells, heterologously
Figure 5. DDAH II overexpression attenuates the LPS-induced increase in ADMA, superoxide, and
peroxynitrite in the mouse lung. Mice were injected with either DST-luciferase (DST) or pAD/CMV/V5-
DEST-DDAH II (DDAH II) plasmid via the tail vein for 60 hours, followed by either saline (vehicle) or
LPS (6.753104 EU/g body weight, 12 h) delivered intraperitoneally. The LPS-dependent increase
in ADMA was significantly attenuated in mice with increased DDAH II expression (A). The LPS-
mediated increase in NOS-derived superoxide generation was also significantly mitigated in mice with
increased DDAH II expression (B). The LPS-induced increase in nitrative stress, as determined by the
peroxynitrite-dependent oxidation of DHR 123 to rhodamine 123 (C) and 3-NT levels (D), was
also significantly diminished in mice with increased DDAH II expression. Values are means 6 SEM
(n = 4–6). *P , 0.05 versus DST 1 vehicle, †P , 0.05 versus DST 1 LPS.
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expressed human DDAH II has been
shown to be S-nitrosylated after cytokine
induced expression of iNOS (39). This
observation may partially explain the loss
of DDAH activity and the increase in
ADMA levels in LPS-treated mice, as
iNOS expression is induced (5). However,
it is likely that other mechanisms are
involved, as a significant decrease in
DDAH activity was observed 2 hours after
LPS exposure, whereas a significant
increase in NO levels and iNOS expression
did not occur until 4 hours after LPS
treatment (5).
Although our data demonstrate that
LPS induces both oxidative and nitrative
stress in the mouse lung, antioxidants and
other similar therapies targeting oxidative
damage have shown only limited efficacy
in human trials. For instance, in a small
clinical trial, N-acetylcysteine caused the
repletion of glutathione in patients with ALI,
but only moderately improved lung function
(42). In addition, the use of NOS
inhibitors has failed to reduce oxidative
stress, and have even tended to increase
mortality in mice (24) and in patients with
severe sepsis (25). Although the
administration of an iNOS inhibitor
improved survival when given 12 hours
after peritonitis-induced sepsis in rats, the
same intervention increased mortality when
given 6 hours earlier (26). In addition,
Figure 6. The overexpression of DDAH II in the mouse lung prevents
endothelial barrier dysfunction and lung injury in response to LPS. Mice were
injected with either DST-luciferase (DST) or pAD/CMV/V5-DEST-DDAH II
(DDAH II) plasmid via tail the vein for 60 hours, followed by saline (vehicle) or
LPS (6.753104 EU/g body weight, 12 h) intraperitoneally. Bronchoalveolar
lavage fluid (BALF) was collected. Total cell count in BALF was increased
after LPS exposure, and this was significantly attenuated in DDAH
II–overexpressing mice (A). Lung myeloperoxidase (MPO) activity (which
indicates neutrophil sequestration in the lung) was similarly attenuated in
DDAH II–overexpressing mice (B). LPS exposure also significantly increased
the levels of keratinocyte-derived chemokine (KC) (C) and monocyte
chemoattractant protein (MCP) -1 (D). DDAH II overexpression attenuated the
increase in KC (C), but not MCP-1 (D). Lung sections were examined for signs
of inflammation after hematoxylin and eosin (H 1 E) staining and neutrophil
infiltration after MPO staining (E) (representative micrographs are shown),
and scored for lung injury (F). DDAH II overexpression significantly attenuated
MPO staining (E) and lung injury score (F). The capillary leak (inferred from
Evan’s Blue dye [EBD] extravasation in the lung and expressed as the ratio of
EBD to lung wet weight) induced by LPS (6.753104 EU/g body weight, 18 h)
was also significantly attenuated in DDAH II–overexpressing mice (G). Values
are mean 6 SEM (n = 4–7). *P , 0.05 versus DST 1 vehicle, †P , 0.05
versus DST 1 LPS.
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the antioxidant, nacystelyn, inhibited
LPS-induced IL-8 and transforming growth
factor-b1, but failed to mitigate the levels of
TNF-a, transforming growth factor-b3,
macrophage inflammatory protein (MIP)-
1a and -b, and regulated on activation,
normal T cell expressed and secreted in
LPS-treated cells (27). In contrast, our data
using DDAH II overexpression reduced the
levels of 13 proinflammatory cytokines,
suggesting that DDAH II may have
additional anti-inflammatory effects.
Although the exact mechanism by which
DDAH II attenuates these cytokines is not
known, at least one previously published
report has suggested that DDAH II
enhances the expression of the anti-
inflammatory factor, cortistatin (28). In
the lungs of endotoxemic mice, cortistatin
reduced the levels of several cytokines, such
as IL-6, IL-12, and MIP (29). Furthermore,
our data indicate that DDAH II
overexpression attenuated the LPS-induced
increase in multiple cytokine pathways,
including IL-2, IL-6, and IL-12. These
cytokines have been previously reported
to play significant roles in promoting
endothelial barrier disruption. For example,
IL-2, an important cytokine necessary
for the differentiation and survival of
Figure 7. DDAH II overexpression enhances lung repair after LPS exposure. Mice received either saline (vehicle) or LPS (1.25 mg/kg body weight)
intratracheally. At 4 days after LPS delivery, the mice had significant lung injury, as indicated by an increase in total cell number in the BALF (A). A separate
set of mice were injected, via the tail vein, with plasmids for either pDST-luciferase (DST) or pAD/CMV/V5-DEST-DDAH II (DDAH II) 4 days after LPS
administration, and then examined 3 days later (7 d after LPS). DDAH II overexpression in the mouse lung increased DDAH II protein levels (B), restored
DDAH II catalytic activity (C), and significantly attenuated cell numbers in the BALF on Day 7 after LPS (A), and attenuated lung MPO activity (D).
Lung sections were stained with H 1 E for indicators of inflammation and MPO for neutrophil infiltration (E) (representative micrographs are shown), and
scored for lung injury (F). DDAH II overexpression attenuated MPO staining and reduced lung cellularity (E) and lung injury score (F). DDAH II–overexpressing
mice also had increased lung compliance (G), decreased lung resistance (H), and increased lung oxygen saturation (I). Values are mean 6 SEM (n = 7–9).
*P , 0.05 versus vehicle, †P , 0.05 versus LPS (4 d [A]), ‡P , 0.05 versus DST 1 LPS (7 d [A]), and †P , 0.05 versus DST 1 LPS (7 d [B–I]).
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CD4/CD81 effector T cells, is responsible
for the development of vascular leak
syndrome in cancer immunotherapy (30).
In addition, IL-6 has been widely known to
mediate hypoxia-induced endothelial
permeability (31). Furthermore, IL-12,
which is involved in differentiation of naive
T cells, has been demonstrated to up-
regulate the release of vascular permeability
factor (vascular endothelial growth factor)
(32). Therefore, the attenuation of these
cytokines provides an additional
mechanism by which DDAH II may
preserve endothelial barrier function and
also limit the inflammation induced by LPS.
Furthermore, the attenuation of numerous
cytokines by DDAH II suggests that this
effect could be mediated by the regulation
of a master transcription factor(s).
Interestingly, high levels of ADMA or
decreased DDAH activity have been
associated with an increase in NF-kB
binding in airway epithelial cells (33). The
NF-kB family of transcription factors is
known to regulate the expression of
multiple cytokines and chemokines. For
instance, a mutation in the IL-6 promoter
at the binding site of NF-kB impairs IL-6
promoter activation in response to LPS
(34), whereas the binding of NF-kB to the
IL-12 promoter in macrophages induces the
expression and release of IL-12 (35). In
addition, the targeting of NF-kB to the
IL-13 promoter in Hodgkin’s disease is an
important proinflammatory event in the
pathogenesis of the disease (36). NF-kB
exists in the cytoplasm in complex with an
inhibitor protein, IkBa, which masks the
NF-kB nuclear localization sequence, and
we have previously shown that the nitration
of IkBa at tyrosine-181 leads to the
dissociation of IkBa from the binding site
on NF-kB, and subsequently activates the
transciption factor (37). Thus, we speculate
that the decreased oxidative and nitrative
stress associated with DDAH II
overexpression could potentially inhibit the
dissociation of IkBa from NF-kB, and
therefore prevent NF-kB activation and
the subsequent up-regulation of the
inflammatory cytokines normally
associated with LPS administration.
Previous studies have shown that
over 90% of ADMA is metabolized by
DDAH. Whether this phenomenon is
predominantly due to the activity of the
DDAH I or DDAH II isoform is a subject of
controversy. Both isoforms of DDAH are
expressed in the lungs (38), although the
protein levels of DDAH II are significantly
higher than those of DDAH I (38).
Interestingly, under physiological
conditions, although its expression is lower,
it is believed that DDAH I rather than
DDAH II regulates the level of ADMA
(38, 39). However, under pathologic
conditions, it appears that the activity of
DDAH II becomes more predominant, as it
was shown in a mouse model of allergically
inflamed lungs (21), and in an ovine
model of smoke inhalation lung injury (40),
that the increased ADMA levels correlated
with reduced DDAH II protein/activity.
Similarly, in our study, we found that the
overexpression of DDAH II attenuated the
LPS-induced increase in ADMA levels in
both endothelial cells and the mouse lung.
Conversely, in an earlier study, the
overexpression of the DDAH I isoform
alone was not able to restore the loss of
NOS signaling secondary to increased
ADMA levels in endothelial cells treated
with the lipid hydroperoxide degradation
product, 4-hydroxy-2-nonenal (41).
However, it is evident from our data that
the attenuation of DDAH activity and the
subsequent increase in ADMA levels is an
important event regulating the levels of
reactive oxygen species and nitrogen
species. These findings are in agreement
with a previous study where the LPS-
mediated increase in reactive oxygen
species in endothelial cells was enhanced
by exogenous ADMA and attenuated by
either exogenous L-arginine or the
overexpression of DDAH II (42). Similarly,
in a murine model of allergic airway
inflammation, decreased levels of DDAH II
correlated with an increase in peroxynitrite
generation, which was attenuated by the
administration of L-arginine (21). In our
study, we found that the elevated cellular
superoxide levels were NOS dependent, and
that the overexpression of DDAH II
restored NOS coupling. Moreover, when we
overexpressed DDAH II, we found that the
endothelial barrier dysfunction associated
with LPS exposure was attenuated.
Although we were unable to determine
the exact mechanisms by which DDAH II
protects the endothelial barrier, our data
suggest possible avenues for this protection.
It is likely that the preservation of NO
signaling is involved (43). In support of this
concept, prior studies have shown that
decreased NO generation in the pulmonary
circulation in eNOS2/2 mice (43), and
the inhibition of NOS in the isolated
perfused rabbit lung (44), causes
microvessel leakage, suggesting that, at
physiological levels, NO plays an essential
role in promoting endothelial barrier
function. However, it should be noted that
the decrease in ADMA levels with DDAH
overexpression might promote endothelial
barrier integrity independently of increased
NO signaling. For instance, a recent study
showed in porcine pulmonary endothelial
cells that ADMA increased stress fiber
formation through the stimulation of
RhoA–Rho kinase signaling (39).
Furthermore, ADMA also inhibited the
activities of Rac1 and Cdc42 in these cells
(28). The Rho family of GTPases is
known to be involved in regulating the
endothelial barrier. The activation of RhoA
increases endothelial permeability by
increasing actomyosin contractility and
intercellular gap formation (45). In
contrast, Rac1 activity is required for the
assembly, maintenance, and recovery of
endothelial intercellular junctions (46).
Cdc42 has been shown to promote junction
recovery after thrombin treatment in
human pulmonary arterial endothelial cells
(35). Thus, in our case, it is possible that
the low levels of ADMA associated with
DDAH II overexpression could keep the
RhoA–Rac1 balance tilted toward barrier
enhancement.
Furthermore, our data suggest that the
LPS-mediated decreases in DDAH activity
and the resulting increases in ADMA may
be involved in the recruitment and
activation of inflammatory cells, such as
neutrophils and monocytes/macrophages in
the lung. Previous studies have shown
that the loss of DDAH activity can augment
the levels of cytokines, such as IL-1, IL-6,
IL-8, and MCP-1 (28, 47), and therefore
potentiate inflammation. LPS-induced
cytokines, such as TNF-a, have also been
shown to decrease DDAH activity and
enhance ADMA levels (28, 48), providing
a possible mechanism by which LPS
regulates the DDAH/ADMA cascade. In
our study, we analyzed a profile of 32
cytokines/chemokines in the BALF of mice
treated with LPS, and found an increase in
28 of these cytokines, including IL-1, IL-6,
MCP-1, and TNF-a (Table E1). The
overexpression of DDAH II attenuated the
LPS-induced increase in 13 of these
cytokines (Table E1). Although it is unclear,
and beyond the scope of this study to
determine, why DDAH II attenuated
certain cytokines and not others, based on
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our data, we can speculate. It is well
established that the sequence of acute
inflammation in the lung and other organs
is characterized by an early influx of
neutrophils, followed by a late increase in
monocytes/macrophages. KC is a major
chemoattractant for neutrophils, whereas
the recruitment of macrophages is highly
dependent on the release of MCP-1 from
the neutrophils. Our data demonstrate
that the levels of KC and MCP-1 were
elevated in the BALF of LPS-treated mice.
DDAH II overexpression attenuated the
levels of KC, but not MCP-1. In addition,
DDAH II also increased macrophage
chemoattractants, such as MIP-2, but
decreased MIP-1, IFN-g–induced protein
10, and macrophage colony–stimulating
factor. Thus, our data suggest that
maintaining DDAH activity appears to
attenuate the early phase of inflammation
by inhibiting KC-dependent neutrophil
recruitment, but preserves the late influx of
macrophages by MCP-1 and MIP-2, which
may facilitate the clearance of cellular
debris. Although, it is surprising that
MCP-1 levels did not decline with the
numbers of neutrophils in the DDAH
II–overexpressed mice, a previous study has
shown that, in inflamed lungs, neutrophil
depletion may not alter MCP-1 levels, and
that elevated concentrations of MCP-1 are
not necessarily accompanied by an increase
in monocytes/macrophages in neutropenic
rats (49). Therefore, it is possible that
MCP-1 levels may not be a true indicator of
macrophage recruitment in ALI, and that
DDAH II overexpression may actually
inhibit macrophage recruitment through
a decrease in neutrophils and the
attenuation of MIP-1, IFN-g–induced
protein 10, and macrophage
colony–stimulating factor. However, it
is worth noting that our analyses were
performed only in the BALF, and not in the
lung tissue. This is a limitation in our study,
as using BALF does not account for the
inflammatory cells that are present in
the septum, which includes cells in the
microvasculature and interstitial spaces.
In conclusion, our data demonstrate
that decreases in DDAH activity and
increases in ADMA are markers of
oxidative/nitrative damage, and are
potential therapeutic targets in ALI.
Strategies aimed at augmenting DDAH II in
patients deemed as being at high risk of
developing ALI (before treatment), or in
patients who have already developed ALI
(after treatment), may provide better clinical
outcomes. Indeed, the pharmacological
targeting of DDAH/ADMA signaling
has been achieved using the cAMP
phosphodiesterase inhibitor, tolafentrine,
which has been shown to modulate the
promoter region of the DDAH II gene
and increase DDAH II expression/activity and
reduce ADMA levels (50). Further studies are
also warranted to shed light on the post-
translational regulation of DDAH activity and
the relative efficacy of enhancing DDAH
activity in patients with ALI. n
Author disclosures are available with the text
of this article at www.atsjournals.org.
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